Back to News
Market Impact: 0.42
Zealand Pharma Gets Positive EU Opinion For Zeydovio In Short Bowel Syndrome
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Zealand Pharma's Zeydovio (glepaglutide) received a positive CHMP recommendation for European marketing authorization to treat adults with short bowel syndrome. The recommendation is a key regulatory milestone that supports potential EMA approval and commercial launch in the EU.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
ZEAL0.82
More News
- Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal